<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00285818</url>
  </required_header>
  <id_info>
    <org_study_id>2HSE450</org_study_id>
    <secondary_id>Oberndorf Family Fund</secondary_id>
    <nct_id>NCT00285818</nct_id>
  </id_info>
  <brief_title>Mifepristone Treatment for Patients With Non-psychotic Major Depressive Disorder Receiving Bilateral ECT</brief_title>
  <official_title>A Double-blind, Placebo-controlled Study of Mifepristone in Patients With Non-psychotic Major Depressive Disorder Referred for Bilateral Electroconvulsive Therapy (ECT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see whether the medication mifepristone is an effective and
      tolerable treatment for increasing the clinical effectiveness of electroconvulsive therapy
      (ECT) and protecting cognitive function during ECT. Both Mifepristone and ECT appear to
      normalize hyperfunctioning of the hypothalmic-pituitary-adrenal (HPA) axis, which has been
      found among patients with major depression referred for ECT. The combination of these two
      treatments in major depression may lead to a more rapid clinical response than ECT alone.
      Additionally, there appears to be a connection between pre-ECT higher cortisol levels due to
      HPA axis hyperfunctioning and post-ECT cognitive impairment. Administration of mifepristone
      prior to and during ECT treatment may reduce cortisol levels and reduce the incidence of
      cognitive impairment observed after ECT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients referred to the Stanford ECT Service who provide informed consent for this study
      will be screened for eligibility.

      Day -4 to 0: Screening (visit 1) will occur three to six days prior to the first ECT
      treatment. Screening procedures will include: Psychiatric interviews and ratings (including
      MINI, Hamilton Depression Rating Scale and Clinician's Global Impression) and
      review/retrieval of results of pre-ECT physical exam, ECG, chest x-ray, laboratory
      evaluations (including comprehensive metabolic panel, comprehensive blood count, and urine
      toxicology), and vital signs from the subject's medical record. A urine pregnancy test will
      be included for females of childbearing potential. Concomitant medications and pre-existing
      health issues will be recorded. Subjects who are deemed eligible for this study will then
      undergo a battery of neuropsychiatric assessments and will be admitted to GCRC for collection
      of blood samples to measure adrenocorticotropin (ACTH) and cortisol levels. These samples
      will be collected hourly beginning at 1pm and ending at 4pm.

      Day 1: Subjects will be randomized 1:1 to receive either mifepristone 600mg or placebo each
      day at bedtime beginning two days prior to the first ECT treatment. Subjects will be
      administered study medication on Day 1 through Day 8.

      Day 3: Subjects will be interviewed with the Hamilton Depression Rating Scale and Clinician's
      Global Impression before their first ECT treatment.

      Day 11: (visit 2) assessments will include psychiatric ratings (including Hamilton Depression
      Rating Scale and Clinician's Global Impression) and a battery of neuropsychiatric
      assessments. Adverse events and concomitant medications will be reviewed and recorded.
      Subjects will be admitted to the GCRC for collection of blood samples to measure ACTH and
      cortisol levels. Samples will be collected hourly beginning at 1pm and ending at 4pm.

      Day 18: (visit 3) assessments will include psychiatric ratings (including Hamilton Depression
      Rating Scale and Clinician's Global Impression). Adverse events and concomitant medications
      will be reviewed and recorded. Clinical laboratory assessments will be completed (including a
      urine pregnancy test for females, comprehensive metabolic panel, comprehensive blood count,
      urine toxicology, and ECG.) Final visit: (visit 4) will occur 24-72 hours after the last ECT
      treatment. Assessments will include psychiatric ratings (including Hamilton Depression Rating
      Scale and Clinician's Global Impression) and a battery of neuropsychiatric assessments.
      Adverse events and concomitant medications will be reviewed and recorded. A urine pregnancy
      test will be completed for females.

      In addition to the ECT treatment consent, the following materials will be collected from the
      participant's medical record for every ECT treatment: ECT treatment orders, ECT procedure
      note and the results of each pre-ECT Montgomery-Asberg Depression Rating Scale (MADRS). ECT
      treatments at Stanford's ECT Service run every Monday, Wednesday and Friday.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Rating Scale Score</measure>
    <time_frame>Screening to Final Visit</time_frame>
    <description>The Hamilton Depression Scale measures the severity of depression. There are 17 items rated 0 to 4. A total score of 0 indicates that the patient does not endorse any symptoms of depression. The maximum score (the most severe depression) is 68. The outcome measure is the difference between Visit 1 and Visit 4 Hamilton Depression Rating Scale scores of the mifepristone and placebo groups.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Mifepristone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive mifepristone one day before and for 5 additional days after starting ECT</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Oral Capsule</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive a placebo capsule one day before and for 5 additional days after starting ECT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone</intervention_name>
    <description>Mifepristone is a glucocorticoid receptor antagonist.</description>
    <arm_group_label>Mifepristone</arm_group_label>
    <other_name>RU-486</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Capsule</intervention_name>
    <description>Placebo is a capsule without a pharmacological active ingredient</description>
    <arm_group_label>Placebo Oral Capsule</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:To be considered for participation in the study, subject must meet all
        of the following criteria:

          1. Meets DSM-IV criteria for Major Depressive Episode without psychotic features.

          2. 18-75 years of age and able to provide legal consent.

          3. Referred to Stanford ECT service by treating physician for bilateral electroconvulsive
             therapy with inpatient hospitalization.

          4. Completed process for consenting to the clinical use of ECT according to California
             State law.

          5. Females of childbearing potential must be using a double-barrier method of
             contraception during the study and for 30 days after the study (modified 6-2003)

        Exclusion Criteria:Subjects will be excluded from participation if they meet any of the
        following criteria:

          1. Treatment with ECT in the 6 months prior to screening.

          2. Meets criteria for drug or alcohol abuse or dependence in the 6 months prior to
             screening.

          3. Use of alcohol or illegal drugs within seven days of randomization or during study.

          4. Presence of unstable or untreated cardiovascular disease, hypertension, or endocrine
             disorder as determined by investigator.

          5. Use of antipsychotic, antidepressant, or other prescription medications unless dose is
             stable for at least 7 days prior to randomization.

          6. Use of any investigational treatment within 30 days of randomization.

          7. Current pregnancy.

          8. Current lactation.

          9. Previous allergic reaction to mifepristone or drugs of similar chemical structure.
             (added 6-2003)

         10. Use of any oral contraceptives or other drugs that may result in adverse
             drug-mifepristone interaction effects. A 30-day wash out period for oral
             contraceptives is required before mifepristone begins.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugh Brent Solvason</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2006</study_first_submitted>
  <study_first_submitted_qc>January 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2006</study_first_posted>
  <results_first_submitted>October 20, 2016</results_first_submitted>
  <results_first_submitted_qc>December 23, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 16, 2017</results_first_posted>
  <last_update_submitted>December 23, 2016</last_update_submitted>
  <last_update_submitted_qc>December 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Actual">February 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Hugh Brent Solvason</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Mifepristone</title>
          <description>Patients receive mifepristone one day before and for 5 additional days after starting ECT
Mifepristone: Mifepristone is a glucocorticoid receptor antagonist.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Patients receive a placebo capsule one day before and for 5 additional days after starting ECT
Mifepristone: Mifepristone is a glucocorticoid receptor antagonist.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Mifepristone</title>
          <description>Patients receive mifepristone one day before and for 5 additional days after starting ECT
Mifepristone: Mifepristone is a glucocorticoid receptor antagonist.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Patients receive a placebo pill one day before and for 5 additional days after starting ECT
Mifepristone: Mifepristone is a glucocorticoid receptor antagonist.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.2" spread="5.2"/>
                    <measurement group_id="B2" value="48.5" spread="6.2"/>
                    <measurement group_id="B3" value="48.3" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hamilton Depression Rating Scale Score</title>
        <description>The Hamilton Depression Scale measures the severity of depression. There are 17 items rated 0 to 4. A total score of 0 indicates that the patient does not endorse any symptoms of depression. The maximum score (the most severe depression) is 68. The outcome measure is the difference between Visit 1 and Visit 4 Hamilton Depression Rating Scale scores of the mifepristone and placebo groups.</description>
        <time_frame>Screening to Final Visit</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Mifepristone</title>
            <description>Patients receive mifepristone one day before and for 5 additional days after starting ECT
Mifepristone: Mifepristone is a glucocorticoid receptor antagonist.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Patients receive a placebo pill one day before and for 5 additional days after starting ECT</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Depression Rating Scale Score</title>
          <description>The Hamilton Depression Scale measures the severity of depression. There are 17 items rated 0 to 4. A total score of 0 indicates that the patient does not endorse any symptoms of depression. The maximum score (the most severe depression) is 68. The outcome measure is the difference between Visit 1 and Visit 4 Hamilton Depression Rating Scale scores of the mifepristone and placebo groups.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5" spread="3.9"/>
                    <measurement group_id="O2" value="23.0" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4; 4 weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.5" spread="4.9"/>
                    <measurement group_id="O2" value="19.0" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Mifepristone</title>
          <description>Patients receive mifepristone one day before and for 5 additional days after starting ECT
Mifepristone: Mifepristone is a glucocorticoid receptor antagonist.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patients receive a placebo pill one day before and for 5 additional days after starting ECT</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <description>Headache was of mild severity, related to non-specific muscle tension in the temporal and occipital area.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Hugh Brent Solvason</name_or_title>
      <organization>Stanford University</organization>
      <phone>650 776 4793</phone>
      <email>solvason@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

